Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma

[1]  J. Wolchok,et al.  Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Motzer,et al.  Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. , 2014 .

[3]  T. Choueiri,et al.  Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. , 2014 .

[4]  P. Tamboli,et al.  Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. , 2014 .

[5]  E. Plimack,et al.  Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). , 2014 .

[6]  D. McDermott,et al.  Potential of New Therapies like Anti-PD1 in Kidney Cancer , 2014, Current Treatment Options in Oncology.

[7]  P. Tamboli,et al.  Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. , 2014 .

[8]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[9]  J. Bryant,et al.  Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. , 2010, Health technology assessment.

[10]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Hudes.  Targeting mTOR in renal cell carcinoma , 2009, Cancer.

[12]  W. Rathmell,et al.  VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy , 2009, Current oncology reports.

[13]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[14]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[15]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[16]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[17]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[18]  A. Belldegrun,et al.  Systemic therapy for metastatic renal cell carcinoma: a review and update. , 2012, Reviews in urology.

[19]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[20]  J. Thompson Coon,et al.  Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. , 2010, Health technology assessment.

[21]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.